newsfilter
← Latest News
GlobeNewswire·

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33